Dupuytren Contracture Medication
- Author: Stephanie Danielle Mathew, DO; Chief Editor: Herbert S Diamond, MD more...
Medication Summary
In February 2010, the US Food and Drug Administration (FDA) approved collagenase Clostridium histolyticum (Xiaflex) for the treatment of Dupuytren contracture. Injected collagenase extracted from C histolyticum weakens and dissolves the Dupuytren cords.[2, 76, 69, 70, 71]
Complications associated with collagenase C histolyticum are common; they include injection site reactions, peripheral edema, bruising, bleeding, and pain. More serious reactions include tendon rupture and complex regional pain syndrome. (To date, tendon rupture has been described in 0.3% of 1082 patients.)[2, 76]
Intermittent reports detail a decrease in the size of nodules with the use of corticosteroid injections. However, corticosteroids are associated with a high risk of complications, including fat atrophy and skin discoloration.[72] In addition, intralesional injection of corticosteroids can result in tendon rupture.
Because Dupuytren contracture is generally painless, analgesic medications usually are not required.
Enzymes
Class Summary
Collagenase Chistolyticum was approved in February 2010 for percutaneous fasciotomy. Collagenase Chistolyticum is a protease that hydrolyzes collagen and breaks down its triple helix conformation, thus disrupting the Dupuytren cord. It is composed of 2 purified microbial collagenases and is indicated only for those patients with a palpable cord.
Collagenase Clostridium histolyticum (Xiaflex)
This is a proteinase that hydrolyzes collagen in its native triple-helical conformation, resulting in lysis of collagen deposits. Injection into a Dupuytren cord (composed mostly of collagen) may result in enzymatic disruption of the cord. Injection is indicated for Dupuytren contracture with a palpable cord.
Corticosteroids
Class Summary
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli.
Triamcinolone (Kenalog-40, Aristospan)
Triamcinolone is used in the treatment of inflammatory dermatosis that is responsive to steroids. It decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.
Verheyden CN. The history of Dupuytren's contracture. Clin Plast Surg. Oct 1983;10(4):619-25. [Medline].
Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. Sep 3 2009;361(10):968-79. [Medline].
Wheeless Clifford. Wheeless' Textbook of Orthopedics: Dupuytren's Contracture. Ortho Preferred. Available at http://wheelessonline.com/ortho/dupuytrens_contracture. Accessed September 22 2010.
Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R. Dupuytren's Disease Risk Factors. J Hand Surg. 2004/10;29B:423-426. [Medline].
Anthony SG, Lozano-Calderon SA, Simmons BP, Jupiter JB. Gender ratio of Dupuytren's disease in the modern U.S. population. Hand (N Y). Jun 2008;3(2):87-90. [Medline]. [Full Text].
Al-Qattan MM. Factors in the pathogenesis of Dupuytren's contracture. J Hand Surg Am. Nov 2006;31(9):1527-34. [Medline].
Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y). Sep 2009;4(3):256-69. [Medline]. [Full Text].
Fitzgerald AM, Kirkpatrick JJ, Naylor IL. Dupuytren's disease. The way forward?. J Hand Surg Br. Aug 1999;24(4):395-9. [Medline].
Trojian TH, Chu SM. Dupuytren's disease: diagnosis and treatment. Am Fam Physician. Jul 1 2007;76(1):86-9. [Medline].
Strickland JW, Leibovic SJ. Anatomy and pathogenesis of the digital cords and nodules. Hand Clin. Nov 1991;7(4):645-57; discussion 659-60. [Medline].
McFarlane RM. The anatomy of Dupuytren's disease. Bull Hosp Jt Dis Orthop Inst. Fall 1984;44(2):318-37. [Medline].
LUCK JV. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am. Jun 1959;41-A(4):635-64. [Medline].
McFarlane RM. Patterns of the diseased fascia in the fingers in Dupuytren's contracture. Displacement of the neurovascular bundle. Plast Reconstr Surg. Jul 1974;54(1):31-44. [Medline].
Bansal V, Naidu SH. Dupuytren's disease. Curr Opin Orthop. 2005;16(4):236-9.
Vi L, Feng L, Zhu RD, Wu Y, Satish L, Gan BS, et al. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Exp Cell Res. Dec 10 2009;315(20):3574-86. [Medline].
Augoff K, Tabola R, Kula J, Gosk J, Rutowski R. Epidermal growth factor receptor (EGF-R) in Dupuytren's disease. J Hand Surg Br. Dec 2005;30(6):570-3. [Medline].
Kopp J, Seyhan H, Müller B, et al. N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. J Cell Mol Med. Jan-Mar 2006;10(1):157-65. [Medline].
Ulrich D, Ulrich F, Piatkowski A, Pallua N. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch Orthop Trauma Surg. Nov 2009;129(11):1453-9. [Medline].
Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg Am. Mar 2007;32(3):343-51. [Medline].
Johnston P, Larson D, Clark IM, Chojnowski AJ. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am. Sep 2008;33(7):1160-7. [Medline].
MACCALLUM P, HUESTON JT. The pathology of Dupuytren's contracture. Aust N Z J Surg. May 1962;31:241-53. [Medline].
Forsman M, Pääkkönen V, Tjäderhane L, et al. The expression of myoglobin and ROR2 protein in Dupuytren's disease. J Surg Res. May 15 2008;146(2):271-5. [Medline].
Burge P. Genetics of Dupuytren's disease. Hand Clin. Feb 1999;15(1):63-71. [Medline].
Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J Hand Surg Am. Feb 2006;31(2):204-10. [Medline].
Lee LC, Zhang AY, Chong AK, Pham H, Longaker MT, Chang J. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am. Feb 2006;31(2):211-8. [Medline].
Shih B, Wijeratne D, Armstrong DJ, Lindau T, Day P, Bayat A. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg Am. Jan 2009;34(1):124-36. [Medline].
Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet. Nov 2005;68(5):424-9. [Medline].
Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg. Jan 2005;115(1):134-41. [Medline].
Dal Cin P, De Smet L, Sciot R, Van Damme B, Van den Berghe H. Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren's disease. Cancer Genet Cytogenet. Jan 15 1999;108(2):137-40. [Medline].
WARREN RF. The pathology of Dupuytren's contracture. Br J Plast Surg. Oct 1953;6(3):224-30. [Medline].
Loos B, Puschkin V, Horch RE. 50 years experience with Dupuytren's contracture in the Erlangen University Hospital--a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord. Jul 4 2007;8:60. [Medline]. [Full Text].
Hnanicek J, Cimburova M, Putova I, et al. Lack of association of iron metabolism and Dupuytren's disease. J Eur Acad Dermatol Venereol. Apr 2008;22(4):476-80. [Medline].
McCarty S, Farhatullah S, Bayat A. Role of the HLA System in the Pathogenesis of Dupuytren's Disease. Hand. 2010/2;5:241-250.
Neumuller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin Immunol Immunopathol. May 1994;71(2):142-8. [Medline].
Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med. May 1996;29(5):521-32. [Medline].
Melhom JM, Ackerman III WE. Guides to the Evaluation of Disease and Injury Causation. American Medical Association Press; 2007:147-152 and 191-202.
Lucas G, Brichet A, Roquelaure Y, Leclerc A, Descatha A. Dupuytren's disease: personal factors and occupational exposure. Am J Ind Med. Jan 2008;51(1):9-15. [Medline].
Lanzettá M, Morrison WA. Dupuytren's disease occurring after a surgical injury to the hand. J Hand Surg Br. Aug 1996;21(4):481-3. [Medline].
Kelly SA, Burke FD, Elliot D. Injury to the distal radius as a trigger to the onset of Dupuytren's disease. J Hand Surg Br. Apr 1992;17(2):225-9. [Medline].
Thomas PR, Clarke D. Vibration white finger and Dupuytren's contracture: are they related?. Occup Med (Lond). Aug 1992;42(3):155-8. [Medline].
Cocco PL, Frau P, Rapallo M, Casula D. [Occupational exposure to vibration and Dupuytren's disease: a case-controlled study]. Med Lav. Sep-Oct 1987;78(5):386-92. [Medline].
Dasgupta AK, Harrison J. Effects of vibration on the hand-arm system of miners in India. Occup Med (Lond). Feb 1996;46(1):71-8. [Medline].
Thurston A. Dupuytren's disease or Cooper's contracture?: Kenneth Fitzpatrick Russell Memorial Lecture. ANZ J Surg. Jul 2003;73(7):529-35. [Medline].
Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br. May 1984;66(3):322-5. [Medline].
Gudmundsson KG, Arngrimsson R, Jonsson T. Dupuytren's disease, alcohol consumption and alcoholism. Scand J Prim Health Care. Sep 2001;19(3):186-90. [Medline].
Bradlow A, Mowat AG. Dupuytren's contracture and alcohol. Ann Rheum Dis. Apr 1986;45(4):304-7. [Medline]. [Full Text].
Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br. Mar 1997;79(2):206-10. [Medline]. [Full Text].
Brown JJ, Ollier W, Thomson W, Bayat A. Positive association of HLA-DRB1*15 with Dupuytren's disease in Caucasians. Tissue Antigens. Aug 2008;72(2):166-70. [Medline].
Kuhn MA, Wang X, Payne WG, Ko F, Robson MC. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. J Surg Res. Apr 2002;103(2):146-52. [Medline].
Pagnotta A, Specchia N, Soccetti A, Manzotti S, Greco F. Responsiveness of Dupuytren's disease fibroblasts to 5 alpha-dihydrotestosterone. J Hand Surg Am. Nov 2003;28(6):1029-34. [Medline].
Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry. May 1976;39(5):498-503. [Medline]. [Full Text].
Ross DC. Epidemiology of Dupuytren's disease. Hand Clin. Feb 1999;15(1):53-62, vi. [Medline].
Bower M, Nelson M, Gazzard BG. Dupuytren's contractures in patients infected with HIV. BMJ. Jan 20 1990;300(6718):164-5. [Medline]. [Full Text].
McFarlane RM. On the origin and spread of Dupuytren's disease. J Hand Surg Am. May 2002;27(3):385-90. [Medline].
Saboeiro AP, Porkorny JJ, Shehadi SI, Virgo KS, Johnson FE. Racial distribution of Dupuytren's disease in Department of Veterans Affairs patients. Plast Reconstr Surg. Jul 2000;106(1):71-5. [Medline].
LING RS. THE GENETIC FACTOR IN DUPUYTREN'S DISEASE. J Bone Joint Surg Br. Nov 1963;45:709-18. [Medline].
Gonzalez MH, Sobeski J, Grindel S, Chunprapaph B, Weinzweig N. Dupuytren's disease in African-Americans. J Hand Surg Br. Jun 1998;23(3):306-7. [Medline].
Hueston JT. The incidence of Dupuytren's contracture. Med J Aust. 1960;2:999-1002.
Bebbington A, Savage R. Dupuytren's disease in an infant. J Bone Joint Surg Br. Jan 2005;87(1):111-3. [Medline].
Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren's contracture surgery. J Hand Surg Am. Sep 2005;30(5):1021-5. [Medline].
Högemann A, Wolfhard U, Kendoff D, Board TN, Olivier LC. Results of total aponeurectomy for Dupuytren's contracture in 61 patients: a retrospective clinical study. Arch Orthop Trauma Surg. Feb 2009;129(2):195-201. [Medline].
Reuben SS, Pristas R, Dixon D, Faruqi S, Madabhushi L, Wenner S. The incidence of complex regional pain syndrome after fasciectomy for Dupuytren's contracture: a prospective observational study of four anesthetic techniques. Anesth Analg. Feb 2006;102(2):499-503. [Medline].
Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am. Dec 2006;31(10):1626-34. [Medline].
Bayat A, Cunliffe EJ, McGrouther DA. Assessment of clinical severity in Dupuytren's disease. Br J Hosp Med (Lond). Nov 2007;68(11):604-9. [Medline].
Meathrel KE, Thoma A. Abductor digiti minimi involvement in Dupuytren's contracture of the small finger. J Hand Surg Am. May 2004;29(3):510-3. [Medline].
Balaguer T, David S, Ihrai T, Cardot N, Daideri G, Lebreton E. Histological staging and Dupuytren's disease recurrence or extension after surgical treatment: a retrospective study of 124 patients. J Hand Surg Eur Vol. Aug 2009;34(4):493-6. [Medline].
Lam WL, Rawlins JM, Karoo RO, Naylor I, Sharpe DT. Re-visiting Luck's classification: a histological analysis of Dupuytren's disease. J Hand Surg Eur Vol. May 2010;35(4):312-7. [Medline].
Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up. J Hand Surg Am. Apr 2010;35(4):534-9, 539.e1. [Medline].
Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. Sep 2002;27(5):788-98. [Medline].
Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren's disease. Hand Clin. Feb 1999;15(1):97-107, vii. [Medline].
Starkweather KD, Lattuga S, Hurst LC, et al. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am. May 1996;21(3):490-5. [Medline].
Rayan GM. Nonoperative treatment of Dupuytren's disease. J Hand Surg Am. Sep 2008;33(7):1208-10. [Medline].
Betz N, Ott OJ, Adamietz B, Sauer R, Fietkau R, Keilholz L. Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years. Strahlenther Onkol. Feb 2010;186(2):82-90. [Medline].
Ketchum LD, Donahue TK. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. J Hand Surg Am. Nov 2000;25(6):1157-62. [Medline].
Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. J Hand Surg Am. Jul-Aug 2007;32(6):767-74. [Medline].
Collagenase Clostridium Histolyticum [package insert]. Malver, PA: Auxilium Pharmaceuticals; 2010. [Full Text].
Bulstrode NW, Mudera V, McGrouther DA, Grobbelaar AO, Cambrey AD. 5-fluorouracil selectively inhibits collagen synthesis. Plast Reconstr Surg. Jul 2005;116(1):209-21; discussion 222-3. [Medline].
Jemec B, Linge C, Grobbelaar AO, Smith PJ, Sanders R, McGrouther DA. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. Chir Main. Feb 2000;19(1):15-22. [Medline].
Namazi H. Imiquimod: a potential weapon against Dupuytren contracture. Med Hypotheses. 2006;66(5):991-2. [Medline].
Namazi H, Abdinejad F. Botulinum Toxin as a novel addition to the antidupuytren armamentarium. Med Hypotheses. 2007;68(1):240-1. [Medline].
Townley WA, Cambrey AD, Khaw PT, Grobbelaar AO. Matrix metalloproteinase inhibition reduces contraction by dupuytren fibroblasts. J Hand Surg Am. Nov 2008;33(9):1608-16. [Medline].
Yildiz S, Karacaoglu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture. Microsurgery. 2004;24(1):26-9. [Medline].
Denkler, Keith. Surgical Complications Associated With Fasciectomy for Dupuytren's Disease: A 20-Year Review of the English Literature. Eplasty [serial online]. Jan 27, 2010;10:e15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20204055. Accessed November 3, 2010. [Medline]. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828055/.
Anwar MU, Al Ghazal SK, Boome RS. Results of surgical treatment of Dupuytren's disease in women: a review of 109 consecutive patients. J Hand Surg Am. Nov 2007;32(9):1423-8. [Medline].
Mavrogenis AF, Spyridonos SG, Ignatiadis IA, et al. Partial fasciectomy for Dupuytren's contractures. J Surg Orthop Adv. Summer 2009;18(2):106-10. [Medline].
Misra A, Jain A, Ghazanfar R, Johnston T, Nanchahal J. Predicting the outcome of surgery for the proximal interphalangeal joint in Dupuytren's disease. J Hand Surg Am. Feb 2007;32(2):240-5. [Medline].
Donaldson OW, Pearson D, Reynolds R, Bhatia RK. The association between intraoperative correction of Dupuytren's disease and residual postoperative contracture. J Hand Surg Eur Vol. Mar 2010;35(3):220-3. [Medline].
Zyluk A, Jagielski W. The effect of the severity of the Dupuytren's contracture on the function of the hand before and after surgery. J Hand Surg Eur Vol. Jun 2007;32(3):326-9. [Medline].
Lilly SI, Stern PJ. Simultaneous carpal tunnel release and Dupuytren's fasciectomy. J Hand Surg Am. May 2010;35(5):754-9. [Medline].
van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week follow-up study. J Hand Surg Am. May-Jun 2006;31(5):717-25. [Medline].
van Rijssen AL, Werker PM. Percutaneous needle fasciotomy in dupuytren's disease. J Hand Surg Br. Oct 2006;31(5):498-501. [Medline].
Cheng HS, Hung LK, Tse WL, Ho PC. Needle aponeurotomy for Dupuytren's contracture. J Orthop Surg (Hong Kong). Apr 2008;16(1):88-90. [Medline].
Symes T, Stothard J. Two significant complications following percutaneous needle fasciotomy in a patient on anticoagulants. J Hand Surg Br. Dec 2006;31(6):606-7. [Medline].
Foucher G, Medina J, Navarro R. Percutaneous needle aponeurotomy: complications and results. J Hand Surg Br. Oct 2003;28(5):427-31. [Medline].
Moermans JP. Long-term results after segmental aponeurectomy for Dupuytren's disease. J Hand Surg Br. Dec 1996;21(6):797-800. [Medline].
Moermans JP. Segmental aponeurectomy in Dupuytren's disease. J Hand Surg Br. Aug 1991;16(3):243-54. [Medline].
Ali SN, McMurtrie A, Rayatt S, Roberts JO. Ulnar-based skin flap for Dupuytren's fasciectomy. Scand J Plast Reconstr Surg Hand Surg. 2006;40(5):307-10. [Medline].
Pelissier P, Gardet H, Pinsolle V. The palmar intermetacarpal flap in Dupuytren's contracture. J Hand Surg Eur Vol. Feb 2007;32(1):113. [Medline].
HUESTON JT. Limited fasciectomy for Dupuytren's contracture. Plast Reconstr Surg Transplant Bull. Jun 1961;27:569-85. [Medline].
Tripoli M, Merle M. The "Jacobsen Flap" for the treatment of stages III-IV Dupuytren's disease: a review of 98 cases. J Hand Surg Eur Vol. Dec 2008;33(6):779-82. [Medline].
Skoff HD. The surgical treatment of Dupuytren's contracture: a synthesis of techniques. Plast Reconstr Surg. Feb 2004;113(2):540-4. [Medline].
Ullah AS, Dias JJ, Bhowal B. Does a 'firebreak' full-thickness skin graft prevent recurrence after surgery for Dupuytren's contracture?: a prospective, randomised trial. J Bone Joint Surg Br. Mar 2009;91(3):374-8. [Medline].
Villani F, Choughri H, Pelissier P. [Importance of skin graft in preventing recurrence of Dupuytren's contracture]. Chir Main. Dec 2009;28(6):349-51. [Medline].
Mullins PA. Postsurgical rehabilitation of Dupuytren's disease. Hand Clin. Feb 1999;15(1):167-74, viii. [Medline].
Jerosch-Herold C, Shepstone L, Chojnowski AJ, Larson D. Splinting after contracture release for Dupuytren's contracture (SCoRD): protocol of a pragmatic, multi-centre, randomized controlled trial. BMC Musculoskelet Disord. Apr 30 2008;9:62. [Medline]. [Full Text].
Evans RB, Dell PC, Fiolkowski P. A clinical report of the effect of mechanical stress on functional results after fasciectomy for Dupuytren's contracture. J Hand Ther. Oct-Dec 2002;15(4):331-9. [Medline].

